By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socioeconomic groups will have decreased by 30%.
The general health of the Dutch is doing well: people are getting older and the number of years in good health is increasing. Nevertheless, the socioeconomic differences in health are large and persistent: 6 years difference in life expectancy, 15 years difference in healthy life expectancy.
‘It is often wrongly thought that this only concerns a small part of the population’, says Mohammed Azzouz, programme manager at Pharos. ‘The problem is much larger and has an impact not only on the life course of the people concerned, but on society as a whole. Reducing health inequalities is an urgent societal challenge and must be placed high on the agenda.’
By 2040, the burden of disease resulting from an unhealthy lifestyle and living environment will have decreased by 30%.
It was the success story of the last 150 years: prevention. Our system is based on all possible means of prevention. Whether it be through schools, vaccination programmes or the sewerage system, all of these aspects have contributed to an additional life expectancy of no less than 35 years. Healthcare, however, compares less well if we take a look at the facts: it has "only" added 5.5 years to the life expectancy. The question that now arises is: have we reached the limits of implementing prevention? Apparently, it is already embedded so deeply in our system that we no longer even notice it. But has it become a dated concept, or does it still have the potential to be a possible success story again? In this interview, Rick Grobbee tells us his view on the prevention story.
Rick Grobbee's career is impressive. He started his career as a doctor before he was appointed as a professor at the Erasmus University in Rotterdam. In 1996, Grobbee founded the Julius Center in Utrecht. Today, Grobbee is chair of the NWA route "Healthcare research, prevention and treatment" .
This is one of the 25 routes that form the instrument for the Dutch Research Agenda. The routes serve to transform important social and economic questions in society into researchable themes. ‘The ideas that have been generated must now be translated into projects and preferably into feasible conclusions,’ Grobbee says.
It is crystal clear that something must happen if we want to make health and care future-proof. But what exactly should happen? Grobbee states that we can make healthcare manageable by decreasing the demand for care in order to curtail the associated costs and efforts. It is very important to keep people healthy for a longer period of time, and we see that there is still a lot to be gained there. For instance, when we look at socioeconomic health differences, there is about a 20-year gap between the highest and lowest socioeconomic groups in terms of living in good health. 'The difference is large but at the same time encouraging, because it shows that it is possible!’
But how can these differences be reduced? Grobbee indicates, among other things, that we must be careful not to send a "one size fits all" message to the world because that does not appeal to everyone. A multistakeholder solution to the problem is needed. A solution in which various disciplines and parties, including citizens, must play a role. 'Otherwise, you won't make it.' Through dialogue, the citizen must be involved in the entire problem process. In addition, more scientific knowledge and therefore research is needed.
Grobbee indicates that the knowledge about prevention is largely available, but that the challenge lies in implementing this. Whereas 150 years ago it was all about installing sewerage or roundabouts, now it's about changing individuals’ behaviour. Even though behavioural change is one of the biggest challenges, fortunately, there are opportunities on the horizon. For instance, when people go through a "new" phase of life, such as when women become pregnant. The majority of pregnant women are then very concerned about a healthy lifestyle, including healthy eating. So that would be a fantastic moment to engage in a dialogue to realise lasting changes.
When asked if the Netherlands can learn something from prevention in health and care from other countries, Grobbee responds with a whole-hearted “yes”. The Iceland story is a good example of this. Fifteen years ago, alcohol and drug use among teenagers in Iceland was the highest in Europe after Lithuania.
The approach taken included entering into a dialogue with the teenagers and listening to their stories, which eventually resulted in alternatives being offered, such as extracurricular activities like sports. The use of alcohol and drugs has now drastically decreased. Grobbee also points out that other countries, in turn, can learn a lot from the Netherlands. It is an ongoing interaction.
By 2030, the extent of care will be organised and provided to people 50% more (or more often) than present in one's own living environment (instead of in healthcare institutions), together with the network around people.
If the kidneys fail to work properly then transplants or dialysis are needed. Patients on the waiting list for a donor kidney or unable to receive a transplant depend on dialysis treatment. In many cases, this means having their blood purified in hospital three times a week using a haemodialysis machine. This is an intensive, time-consuming treatment with a major impact on a patient’s life. Home haemodialysis allows greater freedom and flexibility, but is also intrusive and demands a high degree of self-reliance.
In the coming years, we will be able to simplify this home treatment considerably and make it suitable for dialysis not only at home, but also elsewhere or while travelling. This means fewer barriers to home treatment and optimum freedom and flexibility.
But we will also need to take into account sustainability (e.g. the environmental impact of disposable dialysis materials) and security (i.e. of data traffic). This is because dialysis that used to be restricted to hospitals will be possible more or less anywhere.
Looking further into the future, it will become possible to give someone a new kidney created from stem cells or artificial cells. A solution like this offers health in the broad sense: it facilitates social participation, in line with the motto of the Netherlands Patients Federation: More a person, less a patient! Besides technology, the human factor will always be needed. Motivated professionals familiar with both people and technology will help to ensure that the new intervention is applied carefully and to identify the desirable and less pleasant consequences.
'With Neokidney the Dutch Kidney Foundation and partners want to make (haemo)dialysis bearable by making it portable. Because being on dialysis still means that you are surviving rather than living your life to its fullest. It limits patients’ possibilities to work, travel and have a social life. Portable dialysis lowers the threshold to start haemodialysis at home and incorporate dialysis in daily life. We are changing the status quo for dialysis patients by pushing for the first real breakthrough since Willem Kolff invented the dialysis machine over 70 years ago.'
- Wouter Eijgelaar, Dutch Kidney Foundation
By 2030, the proportion of people with a chronic disease or lifelong disability who can participate in society according to their wishes and capabilities will have increased by 25%.
Inreda Diabetic has been awarded the National Icon for the development of an artificial pancreas for people with diabetes. Inreda Diabetic was founded by Robin Koops and received the first Health~Holland Voucher in 2015. As someone with diabetes, he developed the device himself and tested it on himself. He has been using the device for months with good results. Internist-endocrinologist Arianne van Bon also tested the device on her patients, whose blood sugar levels improved and symptoms decreased. The artificial pancreas takes over the regulation of blood sugar levels (glucose) from people with type 1 diabetes. It is the only bi-hormonal device in the world that works fully automatically and in which all components are integrated. The patient no longer has to measure and think about how much and when to inject.
In addition to Inreda Diabetic, the innovations of Ioniqa (PET upcycling) and Hiber (satellite network HiberBand) have been named National Icons by the government. The three winners were announced by State Secretary Mona Keijzer of Economic Affairs and Climate Policy in the Dutch television programme De Wereld Draait Door. View the excerpt from the broadcast here.
State Secretary Mona Keijzer: ‘Inreda Diabetic, Ioniqa and Hiber are Dutch solutions to global challenges in the areas of healthcare, material reuse and digitalisation. These new National Icons are calling cards of our innovative strength. They are inventions of entrepreneurs with great economic potential. They give the slogan global challenges, Dutch solutions stature. We can expect a lot from them, and the government will support them in this.’
I think corporate social responsibility is very important! Innovations, often largely paid for with public money, should also flow back into society. Sharing that knowledge, helping each other and taking responsibility for it is important for renewing OUR healthcare. That ultimately benefits everyone!
- Robin Koops, Inreda Diabetic
By 2030, quality of life of people with dementia will have improved by 25%.
The results of the dementia studies are slowly starting to transform from a shattered puzzle to a fixed-piece puzzle. Although the pieces are starting to fall more into place, dementia still presents us with an enormous challenge. Wiesje van der Flier has been working on this research for years and says that ‘dementia is an enormous challenge that we must tackle together, shoulder to shoulder. That is only possible through cooperation.’
This cooperation also needs to extend beyond the Netherlands to the international context. We have to stand firm together.
Van der Flier has devoted a large part of her career to dementia research. She is currently head of clinical research at the Alzheimer Center Amsterdam. The aim of the center is to combine patient care and science, for patients with Alzheimer's disease and other forms of dementia.
‘Science is collaboration’ states Van der Flier. The Delta plan for Dementia is a good example of this, she says. It is a unique, eight-year programme (2013-2020) that focuses on scientific research into dementia. Around 60 national organisations have joined. Van der Flier also emphasises the importance of research by pointing out that ‘the only way to move forward is scientific research so that we can ultimately develop effective treatments.’ And effective treatments are most definitely needed. Unfortunately, we do not yet have a medicine that can cure dementia. However, it seems that the first types of disease-modifying treatment may be on the horizon.
Furthermore, we do not know much about how quickly the disease progresses. We have done quite a bit of work on predicting dementia onset, but from a patient’s perspective, this may not be the most relevant outcome. Questions such as “How long can I drive my car?” or “When will I need additional care services?” are outcomes we cannot yet predict for individual patients. Therefore, science can add another very important piece to the puzzle in the coming years. ‘In a European context, we are working very hard on this with the ADDITION project and on a national scale, in collaboration with Health~Holland, in the ABIDE clinical utility project ’ states Van der Flier.
‘If we want to keep the Dutch economy viable in 2040, we will have to focus more on the citizen and individualised risk profiling now’, says Van der Flier. Dementia is currently expense number one for the Ministry of Health, Welfare and Sport. Many practical questions are highly relevant in this context, such as “What can I do to keep my brain healthy?” and “How high is my risk of cognitive deterioration?”. According to Van der Flier, dementia patients must acquire more control over their own illness and health in order to achieve personalised treatment. If more people live in their own strength, then the costs will fall. Finally, we must focus on molecular diagnostics so that dementia can ultimately be prevented.
The importance of the Deltaplan for Dementia is further emphasised when we view this on an international scale. Van der Flier says: ‘With the Deltaplan for Dementia and the government’s investment in dementia research with mission 4, national research has been strengthened. That gives Dutch researchers a major boost to enter into collaborations at an international level, via EU routes, for example’. A good result of international cooperation is that the Alzheimer Association International Conference will be held in Amsterdam in the summer of 2020.
What can Dutch citizens do themselves to help combat dementia? Van der Flier states that they can participate in drug trials, for example they can register at hersenonderzoek.nl to be matched with a possible trial. Finally, van der Flier would like to inform readers that: ‘what’s good for your body is also good for your brain; what’s good for your brain helps prevent dementia’. Hopefully, together we will find the missing pieces of the puzzle.